Blar i Bergen Open Research Archive på forfatter "Brenk, Ruth"
-
DrugPred_RNA—A Tool for Structure-Based Druggability Predictions for RNA Binding Sites
Rekand, Illimar Hugo; Brenk, Ruth (Journal article; Peer reviewed, 2021)RNA is an emerging target for drug discovery. However, like for proteins, not all RNA binding sites are equally suited to be addressed with conventional drug-like ligands. To this end, we have developed the structure-based ... -
An Experimental Toolbox for Structure-Based Hit Discovery for P. aeruginosa FabF, a Promising Target for Antibiotics
Espeland, Ludvik Olai; Georgiou, Charis; Klein, Raphael; Bhukya, Hemalatha; Haug, Bengt Erik; Underhaug, Jarl; Mainkar, Prathama S.; Brenk, Ruth (Journal article; Peer reviewed, 2021)FabF (3-oxoacyl-[acyl-carrier-protein] synthase 2), which catalyses the rate limiting condensation reaction in the fatty acid synthesis II pathway, is an attractive target for new antibiotics. Here, we focus on FabF from ... -
How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System
Kersten, Christian; Fleischer, Edmond; Kehrein, Josef; Borek, Christoph; Jaenicke, Elmar; Sotriffer, Christoph; Brenk, Ruth (Peer reviewed; Journal article, 2020)A model system of two related enzymes with conserved binding sites, namely N-myristoyltransferase from two different organisms, was studied to decipher the driving forces that lead to selective inhibition in such cases. ... -
Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design
Irsheid, Lina; Wehler, Thomas; Borek, Christoph; Kiefer, Werner; Brenk, Ruth; Ortiz-Soto, Maria Elena; Seibel, Jurgen; Schirmeister, Tanja (Peer reviewed; Journal article, 2019-05-08)Golgi α-mannosidase II (GMII) is a glycoside hydrolase playing a crucial role in the N-glycosylation pathway. In various tumour cell lines, the distribution of N-linked sugars on the cell surface is modified and correlates ... -
In silico identification and experimental validation of hits active against KPC-2 β-lactamase
Klein, Raphael; Linciano, Pasquale; Celenza, Guiseppe; Bellio, Pierangelo; Papaioannou, Sofia; Blazques, Jesus; Cendron, Laura; Brenk, Ruth; Tondi, Donatella (Peer reviewed; Journal article, 2018-11-29)Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, ... -
Riboswitches as Drug Targets for Antibiotics
Panchal, Vipul Navinchandra; Brenk, Ruth (Journal article; Peer reviewed, 2021)Riboswitches reside in the untranslated region of RNA and regulate genes involved in the biosynthesis of essential metabolites through binding of small molecules. Since their discovery at the beginning of this century, ... -
Targeting the Class A Carbapenemase GES-5 via Virtual Screening
Klein, Raphael; Cendron, Laura; Montanari, Maria; Bellio, Pierangelo; Celenza, Giuseppe; Maso, Lorenzo; Tondi, Donatella; Brenk, Ruth (Journal article; Peer reviewed, 2020)The worldwide spread of β-lactamases able to hydrolyze last resort carbapenems contributes to the antibiotic resistance problem and menaces the successful antimicrobial treatment of clinically relevant pathogens. Class A ... -
To hit or not to hit, that is the question -genome-wide structure-based druggability predictions for pseudomonas aeruginosa proteins
Sarkar, Aurijit; Brenk, Ruth (Peer reviewed; Journal article, 2015-09-11)Pseudomonas aeruginosa is a Gram-negative bacterium known to cause opportunistic infections in immune-compromised or immunosuppressed individuals that often prove fatal. New drugs to combat this organism are therefore ...